Polyrizon Ltd. (Nasdaq: PLRZ), a biotechnology company specializing in intranasal drug delivery systems, has announced promising preclinical results from its recent study on the Trap & Target (T&T) platform, an innovative hydrogel-based formulation. Conducted in collaboration with the University of Parma, Italy, the study demonstrated successful targeted deposition in the upper nasal cavity, crucial for central nervous system $(CNS)$ drug delivery. The hydrogel formulation achieved over 60% preferential accumulation in areas favorable for nose-to-brain transport, indicating potential applications for CNS-related conditions such as opioid overdose and epileptic seizures. Polyrizon plans to continue preclinical development and initiate safety studies to further validate these findings.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。